“Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2018 provides an overview of Injectable Drug Delivery currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Injectable Drug Delivery pipeline products.
Scope
Extensive coverage of the Injectable Drug Delivery under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Injectable Drug Delivery and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry.
Reasons to buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Injectable Drug Delivery under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
'
1 Table of Contents
2 Introduction
2.1 Injectable Drug Delivery Overview
3 Products under Development
3.1 Injectable Drug Delivery - Pipeline Products by Stage of Development
3.2 Injectable Drug Delivery - Pipeline Products by Segment
3.3 Injectable Drug Delivery - Pipeline Products by Territory
3.4 Injectable Drug Delivery - Pipeline Products by Regulatory Path
3.5 Injectable Drug Delivery - Pipeline Products by Estimated Approval Date
3.6 Injectable Drug Delivery - Ongoing Clinical Trials
4 Injectable Drug Delivery - Pipeline Products under Development by Companies
4.1 Injectable Drug Delivery Companies - Pipeline Products by Stage of Development
4.2 Injectable Drug Delivery - Pipeline Products by Stage of Development
5 Injectable Drug Delivery Companies and Product Overview
5.1 3M Co Company Overview
5.2 Adamis Pharmaceuticals Corp Company Overview
5.3 AdrenaCard, Inc. Company Overview
5.4 Allergan Inc Company Overview
5.5 Alsensa ApS Company Overview
5.6 Antares Pharma Inc Company Overview
5.7 Aquavit Pharmaceuticals Inc Company Overview
5.8 Artemes Technologies, Inc. Company Overview
5.9 Ascendis Pharma A/S Company Overview
5.10 Ascil Proyectos SL Company Overview
5.11 ASIS Corp Company Overview
5.12 AstraZeneca Plc Company Overview
5.13 AzureBio SL Company Overview
5.14 Becton Dickinson and Co Company Overview
5.15 BioCorRx Inc Company Overview
5.16 BioMarin Pharmaceutical Inc Company Overview
5.17 BioRestorative Therapies Inc Company Overview
5.18 Bioxis Pharmaceuticals Company Overview
5.19 BTG Plc Company Overview
5.20 Burke Pharmaceuticals LLC Company Overview
5.21 Callisyn Biomedical Inc Company Overview
5.22 Cambridge Consultants Ltd Company Overview
5.23 Case Western Reserve University Company Overview
5.24 Cincinnati Children's Hospital Medical Center Company Overview
5.25 Clearside BioMedical Inc Company Overview
5.26 Consort Medical plc Company Overview
5.27 DALI Medical Devices Ltd. Company Overview
5.28 Delcath Systems Inc Company Overview
5.29 DelSite, Inc. (Inactive) Company Overview
5.30 Elcam Medical Company Overview
5.31 EmboMedics Inc Company Overview
5.32 Emergent BioSolutions Inc Company Overview
5.33 Eveon SAS Company Overview
5.34 FHC Inc Company Overview
5.35 GeneSYS-ID Inc Company Overview
5.36 Ghent University Company Overview
5.37 Inovio Pharmaceuticals Inc Company Overview
5.38 InVivo Therapeutics Corp Company Overview
5.39 Ipsen SA Company Overview
5.40 kaleo Inc Company Overview
5.41 LyoGo Company Overview
5.42 Meridian Medical Technologies Inc Company Overview
5.43 Mertiva AB Company Overview
5.44 Milestone Scientific Inc Company Overview
5.45 Novo Nordisk AS Company Overview
5.46 Novosanis NV Company Overview
5.47 Osteo Pharma BV Company Overview
5.48 Oval Medical Technologies Ltd Company Overview
5.49 Particle Therapeutics Ltd Company Overview
5.50 Pfizer Inc Company Overview
5.51 Portal Instruments Inc Company Overview
5.52 pSivida Corp Company Overview
5.53 Queen Elizabeth Hospital Company Overview
5.54 QuiO Technologies LLC Company Overview
5.55 RepliCel Life Sciences Inc Company Overview
5.56 Rescitech Vision Pvt Ltd Company Overview
5.57 RetinaPharma Technologies Inc Company Overview
5.58 Roche Diagnostics International Ltd Company Overview
5.59 Scandinavian Health Ltd Company Overview
5.60 Sun Pharma Advanced Research Company Ltd Company Overview
5.61 TCB medical devices Company Overview
5.62 Terumo Corp Company Overview
5.63 Teva Pharmaceutical Industries Ltd Company Overview
5.64 TheraKine Inc (Inactive) Company Overview
5.65 Twin Star Medical Inc Company Overview
5.66 Unilife Corporation Company Overview
5.67 University of Calgary Company Overview
5.68 University of California San Diego Company Overview
5.69 University of California San Francisco Company Overview
5.70 University of Delaware Company Overview
5.71 University of Dundee Company Overview
5.72 University of Florida Company Overview
5.73 University of Saskatchewan Company Overview
5.74 University of Texas at Austin Company Overview
5.75 Vanderbilt University Company Overview
5.76 West Pharmaceutical Services Inc Company Overview
5.77 Windgap Medical Inc Company Overview
5.78 XERIS Pharmaceuticals Inc Company Overview
5.79 Ypsomed Holding AG Company Overview
6 Injectable Drug Delivery- Recent Developments
6.1 Mar 08, 2018: Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and Immunology
6.2 Mar 06, 2018: Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization
6.3 Mar 06, 2018: Sanofi’s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director
6.4 Mar 06, 2018: Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs
6.5 Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director
6.6 Mar 02, 2018: FDA to Review DUPIXENT (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
6.7 Mar 02, 2018: Clearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis
6.8 Mar 01, 2018: Alkermes Names James Robinson as President and Chief Operating Officer
6.9 Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance
6.10 Feb 28, 2018: Catalent Completes $4.6 Million Expansion at Singapore Facility
6.11 Feb 27, 2018: Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta (pegfilgrastim)
6.12 Feb 26, 2018: West Names Silji Abraham Chief Digital And Transformation Officer
6.13 Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM
6.14 Feb 26, 2018: Recipharm: Chief Financial Officer to leave Recipharm
6.15 Feb 25, 2018: Dr. Reddy’s Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India
6.16 Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director
6.17 Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results
6.18 Feb 22, 2018: BioMarin Reports Fourth Quarter 2017 Financial Results
6.19 Feb 22, 2018: Recipharm Reports Fourth Quarter And Full Year 2017
6.20 Feb 21, 2018: United Therapeutics Reports 2017 Fourth Quarter And Annual Financial Results
6.21 Feb 21, 2018: Merck Invests Additional €40 Million to Enhance Manufacturing and Distribution in Asia
6.22 Feb 20, 2018: Halozyme Reports Fourth Quarter And Full-Year 2017 Results
6.23 Feb 20, 2018: Catalent Announces Changes to its Board of Directors
6.24 Feb 19, 2018: Dr Reddy's Laboratories: Update on US Lawsuit
6.25 Feb 15, 2018: West Announces Fourth-Quarter and Full-Year 2017 Results and Announces Quarterly Dividend
6.26 Feb 14, 2018: Antares Pharma Announces FDA Approval of Partners Product Utilizing Our QuickShot Auto Injector
6.27 Feb 14, 2018: Alkermes Names Shane Cooke As Board Director
6.28 Feb 14, 2018: Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017
6.29 Feb 14, 2018: Recipharm Appoints President Development Services to Drive End to End Offering
6.30 Feb 14, 2018: Alkermes Reports Q4 2017 Financial Results
6.31 Feb 12, 2018: BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
6.32 Feb 08, 2018: First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent, now available in Canada
6.33 Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results
6.34 Feb 07, 2018: SelfDose Patient-Controlled Injector Named as Recipient of Pharmapack Exhibitor Innovation Award
6.35 Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance
6.36 Feb 07, 2018: pSivida Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
6.37 Feb 06, 2018: BD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard
6.38 Feb 06, 2018: Covestro plastic enables medical device innovation
6.39 Feb 06, 2018: MRI Interventions Announces Record 629 ClearPoint Cases in 2017
6.40 Feb 06, 2018: Teva Pharmaceuticals laid off 46 employees in Parsippany
6.41 Feb 05, 2018: Catalent Reports Second Quarter Fiscal 2018 Financial Results
6.42 Feb 02, 2018: Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe
6.43 Feb 02, 2018: AstraZeneca: Full-Year 2017 Results
6.44 Feb 02, 2018: Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results
6.45 Feb 01, 2018: Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies)
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer
List of Tables
Table 1: Injectable Drug Delivery - Pipeline Products by Stage of Development
Table 2: Injectable Drug Delivery - Pipeline Products by Segment
Table 3: Injectable Drug Delivery - Pipeline Products by Territory
Table 4: Injectable Drug Delivery - Pipeline Products by Regulatory Path
Table 5: Injectable Drug Delivery - Pipeline Products by Estimated Approval Date
Table 6: Injectable Drug Delivery - Ongoing Clinical Trials
Table 7: Injectable Drug Delivery Companies - Pipeline Products by Stage of Development
Table 8: Injectable Drug Delivery - Pipeline Products by Stage of Development
Table 9: 3M Co Pipeline Products & Ongoing Clinical Trials Overview
Table 10: 3M Hollow Microstructured Transdermal System - Product Status
Table 11: 3M Hollow Microstructured Transdermal System - Product Description
Table 12: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 13: Symjepi - Junior Version - Product Status
Table 14: Symjepi - Junior Version - Product Description
Table 15: AdrenaCard, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 16: Adrenacard Auto-Injector - Product Status
Table 17: Adrenacard Auto-Injector - Product Description
Table 18: Allergan Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 19: NOVADUR Intravitreal Implant - Product Status
Table 20: NOVADUR Intravitreal Implant - Product Description
Table 21: Alsensa ApS Pipeline Products & Ongoing Clinical Trials Overview
Table 22: SQJCT - Product Status
Table 23: SQJCT - Product Description
Table 24: Antares Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 25: QuickShot Testosterone (QST) - Product Status
Table 26: QuickShot Testosterone (QST) - Product Description
Table 27: Teva Pen 1 - Product Status
Table 28: Teva Pen 1 - Product Description
Table 29: Vibex EPI - Product Status
Table 30: Vibex EPI - Product Description
Table 31: Vibex QS M - Product Status
Table 32: Vibex QS M - Product Description
Table 33: Aquavit Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 34: PITO-001 - Product Status
Table 35: PITO-001 - Product Description
Table 36: Artemes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Artemes Magnetic Injection System - Product Status
Table 38: Artemes Magnetic Injection System - Product Description
Table 39: Ascendis Pharma A/S Pipeline Products & Ongoing Clinical Trials Overview
Table 40: TransCon hGH Auto-Injector - Product Status
Table 41: TransCon hGH Auto-Injector - Product Description
Table 42: Ascendis Pharma A/S - Ongoing Clinical Trials Overview
Table 43: TransCon hGH Auto-Injector - A Multicenter, Phase III, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children with Growth Hormone Deficiency (GHD)
Table 44: Ascil Proyectos SL Pipeline Products & Ongoing Clinical Trials Overview
Table 45: Prefilled Device - Product Status
Table 46: Prefilled Device - Product Description
Table 47: ASIS Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 48: Automatic Subdermal Injection System - Product Status
Table 49: Automatic Subdermal Injection System - Product Description
Table 50: ASIS Corp - Ongoing Clinical Trials Overview
Table 51: Automatic Subdermal Injection System - ASIS for Botox in Chronic Migraine
Table 52: Automatic Subdermal Injection System - ASIS for Botox in Upper Limb Spasticity
Table 53: Automatic Subdermal Injection System - ASIS for Enbrel in Plaque Psoriasis
Table 54: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 55: Bydureon BCise Autoinjector Device - Product Status
Table 56: Bydureon BCise Autoinjector Device - Product Description
Table 57: AzureBio SL Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Injectable Needle - Product Status
Table 59: Injectable Needle - Product Description
Table 60: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview
Table 61: BD Intevia Disposable Autoinjector - Product Status
Table 62: BD Intevia Disposable Autoinjector - Product Description
Table 63: BD Libertas Wearable Injector - Product Status
Table 64: BD Libertas Wearable Injector - Product Description
Table 65: T2 Patch Wearable Injector - Product Status
Table 66: T2 Patch Wearable Injector - Product Description
Table 67: BioCorRx Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 68: Injectable Naltrexone Implant - BICX101 - Product Status
Table 69: Injectable Naltrexone Implant - BICX101 - Product Description
Table 70: Naltrexone Implant - BICX102 - Product Status
Table 71: Naltrexone Implant - BICX102 - Product Description
Table 72: BioMarin Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Pegvaliase Pre-filled Syringe - Product Status
Table 74: Pegvaliase Pre-filled Syringe - Product Description
Table 75: BioRestorative Therapies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Curved Needle Device - Product Status
Table 77: Curved Needle Device - Product Description
Table 78: Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview
Table 79: Vaccine Delivery Device - Product Status
Table 80: Vaccine Delivery Device - Product Description
Table 81: BTG Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 82: Varithena - Aesthetic Leg Veins - Product Status
Table 83: Varithena - Aesthetic Leg Veins - Product Description
Table 84: Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 85: BURKE201 Needle Injection Pen - Product Status
Table 86: BURKE201 Needle Injection Pen - Product Description
Table 87: Callisyn Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 88: TACEspheres Drug Eluting Embolic Microspheres - Product Status
Table 89: TACEspheres Drug Eluting Embolic Microspheres - Product Description
Table 90: Cambridge Consultants Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 91: Flexi-ject - Product Status
Table 92: Flexi-ject - Product Description
Table 93: Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview
Table 94: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Status
Table 95: Pressure Driven Local Drug Delivery System - Liver Cancer - Product Description
Table 96: Cincinnati Children's Hospital Medical Center Pipeline Products & Ongoing Clinical Trials Overview
Table 97: Pre-Filled Syringe With Flush - Product Status
Table 98: Pre-Filled Syringe With Flush - Product Description
Table 99: Clearside BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 100: SCS Microinjector - Product Status
Table 101: SCS Microinjector - Product Description
Table 102: Clearside BioMedical Inc - Ongoing Clinical Trials Overview
Table 103: SCS Microinjector - A Phase III, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema Associated with Non-infectious Uveitis
